Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of tuberculosis
3.2.1.2 Increasing investment for healthcare infrastructure
3.2.1.3 Rise in research and development activities
3.2.1.4 Growing awareness and initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Future market trends
3.8 Pipeline analysis
3.9 Gap analysis
3.10 Porter's analysis
3.11 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Vendor matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Active TB
5.3 Latent TB
Chapter 6 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 First-line therapy
6.3 Second-line therapy
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other route of administration
Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Tablets
8.3 Capsules
8.4 Injection
8.5 Other dosage forms
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Aventis Pharmaceuticals Limited
11.2 Bayer Health Care
11.3 Eli Lilly And Company
11.4 Johnson & Johnson Services; Inc.
11.5 Lupin
11.6 Macleods Pharmaceuticals Ltd.
11.7 Mylan N.V.
11.8 Otsuka Pharmaceutical Co., Ltd.
11.9 Pfizer Inc.
11.10 Sanofi.
